Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators

References

• Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Dia Care. 2018;41(5):963–970.
   PubMed Web of Science ®Google Scholar
• Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281.
   PubMed Web of Science ®Google Scholar
• Morimoto A. Trends in the epidemiology of patients with diabetes in Japan. Japan Med Assoc J. 2010;53(1):36–40.
   Google Scholar
• National Diabetes Survey [Internet]. Tokyo (Japan): MHLD, Japan; 1997 [cited 2019 Jul 24]. Available from: https://www.mhlw.go.jp/toukei_hakusho/toukei/index.html
   Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes – 2019. Diabetes Care. 2019;42(1):S90–S102.
   PubMed Web of Science ®Google Scholar
• Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996;19(1):64–66.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Haneda M, Noda M, Origasa H, et al. Japanese clinical practice guideline for diabetes 2016. J Diabetes Investig. 2018;9(3):657–697.
   PubMed Web of Science ®Google Scholar
• Tamura Y. A study on the prescription status of metformin and DPP-4 inhibitors in patients with type 2 diabetes mellitus in Japan. Therapeutic Res. 2017;38(12):1231–1237.
   Google Scholar
• Kohro T, Yamazaki T, Sato H, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54(2):93–97.
   PubMed Web of Science ®Google Scholar
• Oishi M, Yamazaki K, Okuguchi F, et al. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32). J Diabetes Invest. 2014;5(5):581–587.
   PubMed Web of Science ®Google Scholar
• Rimei Nishimura HK, Kisanuki K, Oh A, et al. Effectiveness of a dipeptidyl peptidase-4 inhibitoras add-on therapy to metformin and of dose-escalation of metformin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice settings. Therapeutic Res. 2018;39(4):325–336.
   Google Scholar
• Nishimura R, Kato H, Kisanuki K, et al. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. BMJ Open. 2019;9(3):e025806.
   PubMed Web of Science ®Google Scholar
• World Health Organization. International statistical classification of diseases and related health problems 10th revision [Internet]. Geneva (Switzerland): WHO; 2010 [cited 2019 Apr 18]. Available from: https://icd.who.int/browse10/2010/en#!F71
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index 2020 [Internet]. Geneva (Switzerland): WHO; 2016 [cited 2019 Apr 18]. Available from: https://www.whocc.no/atc_ddd_index/
   Google Scholar
• PMDA (Pharmaceuticals and Medical Devices Agency). List of metformin drugs [Internet]. Tokyo (Japan): PMDA; 2020 [cited 2019 Aug 22]. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/3962002
   Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–1588.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• Terauchi Y, Yamada Y, Ishida H, et al. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged >/= 60 years (START-J trial). Diabetes Obes Metab. 2017;19(8):1188–1192.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K. Efficacy, safety and dose–response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(9):810–818.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Haneda M, Ito H, et al. Safety and efficacy of long-term treatment with teneligliptin: interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2018;19(2):83–91.
   PubMed Web of Science ®Google Scholar
• Ito Y, Ambe K, Kobayashi M, et al. Ethnic difference in the pharmacodynamics–efficacy relationship of dipeptidyl peptidase-4 inhibitors between Japanese and non-Japanese patients: a systematic review. Clin Pharmacol Ther. 2017;102(4):701–708.
   PubMed Web of Science ®Google Scholar
• Yabe D, Nishikino R, Kaneko M, et al. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf. 2015;14(6):795–800.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Dimitriadis G, Hahalis G, et al. Sodium–glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. Metabolism. 2019;96:92–100.
   PubMed Web of Science ®Google Scholar
• Ikegami N, Yoo BK, Hashimoto H, et al. Japanese universal health coverage: evolution, achievements, and challenges. Lancet. 2011;378(9796):1106–1115.
   PubMed Web of Science ®Google Scholar
• Kemp A, Preen DB, Glover J, et al. How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countries. Aust Health Review. 2011;35(3):341–349.
   PubMed Web of Science ®Google Scholar
• Ishii H, Hayashino Y, Akai Y, et al. Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study). J Diabetes Investig. 2018;9(1):137–145.
   PubMed Web of Science ®Google Scholar
• Odawara M, Kawamori R, Tajima N, et al. Long-term treatment study of global standard dose metformin in Japanese patients with type 2 diabetes mellitus. Diabetol Int. 2017;8(3):286–295.
   PubMed Web of Science ®Google Scholar
• Selby JV, Ettinger B, Swain BE, et al. First 20 months’ experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care. 1999;22(1):38–44.
   PubMed Web of Science ®Google Scholar
• Flory JH, Keating SJ, Siscovick D, et al. Identifying prevalence and risk factors for metformin non-persistence: a retrospective cohort study using an electronic health record. BMJ Open. 2018;8(7):e021505.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491–497.
   PubMed Web of Science ®Google Scholar
• Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose–response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab. 2005;7(1):28–39.
   PubMed Web of Science ®Google Scholar
• Ito H, Ohno Y, Yamauchi T, et al. Efficacy and safety of metformin for treatment of type 2 diabetes in elderly Japanese patients. Geriatr Gerontol Int. 2011;11(1):55–62.
   PubMed Web of Science ®Google Scholar
• Boccuzzi SJ, Wogen J, Fox J, et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001;24(8):1411–1415.
   PubMed Web of Science ®Google Scholar
• Simard P, Presse N, Roy L, et al. Persistence and adherence to oral antidiabetics: a population-based cohort study. Acta Diabetol. 2015;52(3):547–556.
   PubMed Web of Science ®Google Scholar
• Ayele AA, Tegegn HG, Ayele TA, et al. Medication regimen complexity and its impact on medication adherence and glycemic control among patients with type 2 diabetes mellitus in an Ethiopian general hospital. BMJ Open Diab Res Care. 2019;7(1):e000685.
   PubMed Web of Science ®Google Scholar
• Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23(5):611–614.
   PubMed Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105–116.
   PubMed Web of Science ®Google Scholar
• Ohisa M, Kimura Y, Matsuo J, et al. Estimated numbers of patients with liver disease related to hepatitis B or C virus infection based on the database reconstructed from medical claims from 2008 to 2010 in Japan. Hepatol Res. 2015;45(12):1228–1240.
   PubMed Web of Science ®Google Scholar